SCHEMBL6258693

SCHEMBL6258693

Cc1nccn1-c1ccccc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.47
CYP2E1 P05181 1/20 0.47
CYP2A6 P11509 1/20 0.47
GAA P10253 4/20 0.46
KDM4E B2RXH2 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
USP2 O75604 2/20 0.46
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.46
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ADRA2C P18825 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14428964 0.81 CYP3A4 (0.50) CYP3A4CYP2E1CYP2A6KDM4EALDH1A1
SCHEMBL6260533 0.81 GAA (0.47) CYP3A4GAAKDM4EMEN1KMT2A
SCHEMBL15778631 0.79 CYP3A4 (0.53) CYP3A4CYP2E1CYP2A6KDM4EMEN1
SCHEMBL11764095 0.79 GAA (0.41) GAAKDM4EMEN1KMT2AUSP2
SCHEMBL19029697 0.78 CYP3A4 (0.47) CYP3A4CYP2E1CYP2A6KDM4EALDH1A1
SCHEMBL28144636 0.78 CYP3A4 (0.47) CYP3A4CYP2E1CYP2A6GAAKDM4E
SCHEMBL12342913 0.78 CYP3A4 (0.47) CYP3A4CYP2E1CYP2A6KDM4EALDH1A1
SCHEMBL113850 0.77 CYP3A4 (0.44) CYP3A4CYP2E1CYP2A6KDM4EALDH1A1
SCHEMBL15445107 0.76 CYP3A4 (0.46) CYP3A4CYP2E1CYP2A6KDM4EALDH1A1
SCHEMBL9405397 0.75 NPC1 (0.49) CYP3A4CYP2E1CYP2A6KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327411-A1 SIRT6 ACTIVATORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-10-03 US disclosed
US-11993729-B2 Chemical mechanical polishing composition BASF SE (DE) 2024-05-28 US disclosed
EP-3714012-B1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2023-01-11 EP disclosed
US-20210102093-A1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2021-04-08 US disclosed
US-10899945-B2 Use of a chemical mechanical polishing (CMP) composition for polishing of cobalt comprising substrates BASF SE (DE) 2021-01-26 US disclosed
EP-3714012-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2020-09-30 EP disclosed
US-20200299547-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2020-09-24 US disclosed
EP-3334794-B1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2020-02-19 EP disclosed
WO-2019101555-A1 CHEMICAL MECHANICAL POLISHING COMPOSITION BASF SE (DE) 2019-05-31 WO disclosed
EP-3334794-A1 USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT COMPRISING SUBSTRATES BASF SE (DE) 2018-06-20 EP disclosed
EP-1307431-B1 EFFICIENT LIGAND-MEDIATED ULLMANN COUPLING OF ANILINES AND AZOLES BRISTOL MYERS SQUIBB PHARMA CO (US) 2005-10-26 EP disclosed
EP-1307431-A2 EFFICIENT LIGAND-MEDIATED ULLMANN COUPLING OF ANILINES AND AZOLES Bristol-Myers Squibb Pharma Company (US) 2003-05-07 EP disclosed
US-6541639-B2 Condensation reaction of 2-fluoro-4-iodoaniline with 2-(N,N-dimethylamino) in presence of 8-hydroxyquinoline and copper iodide BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-04-01 US disclosed
US-20020099225-A1 Efficient ligand-mediated ullmann coupling of anilnies and azoles BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-07-25 US disclosed
WO-2002008199-A2 EFFICIENT LIGAND-MEDIATED ULLMANN COUPLING OF ANILINES AND AZOLES BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-01-31 WO disclosed
EP-0354224-A1 NITROGEN-CONTAINING ESTERS OF CARBOXY-CONTAINING INTERPOLYMERS The Lubrizol Corporation (US) 1990-02-14 EP disclosed
US-4602031-A Anti-depressant imidazoles, compositions and use EISAI CO., LTD. (JP) 1986-07-22 US disclosed
US-4533669-A NONTOXIC EISAI CO., LTD. (JP) 1985-08-06 US disclosed
US-4402966-A Acylaminophenyl imidazoles and anti-depressing agent containing the same EISAI CO., LTD. (JP) 1983-09-06 US disclosed
US-4301169-A Novel imidazole compound and anti-depressing agent containing the same EISAI CO., LTD. (JP) 1981-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327411-A1 SIRT6 ACTIVATORS SIRT6, SIRT1, SIRT2 CYP3A4 4281/4885CYP2E1 4094/4885CYP2A6 727/4885
US-20020099225-A1 Efficient ligand-mediated ullmann coupling of anilnies and azoles F12, F2, UTS2R CYP3A4 61/4885CYP2E1 1256/4885CYP2A6 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.